Atorvastatin vs placebo in the primary prevention of CHD: CARDS Study

Colhoun HM, et al. conducted the CARDS ( The Collaborative Atorvastatin Diabetes Study) study, which compared the efficacy of atorvastatin vs placebo in primary prevention of CHD, coronary re-vascularization and stroke in patients with type 2 diabetes (1).

Study Summary

---

About the Author

Ms. Roma Joglekar is a Sports Physiotherapist with three years of on-field experience in helping athletes recover, improve and excel in their performance. Roma is passionate about medical science and has keen interest in simplifying complex medical information and share it with healthcare professionals, patients, care givers and the general population.

Click on this link to connect with the Author

---

Abbreviations

CARDS: The Collaborative Atorvastatin Diabetes Study; CHD: Coronary Heart Disease; LDL-C: Lowe Density Lipoprotein Cholesterol; TG: Triglycerides; CV: Cardiovascular; CVD: cardiovascular disease; 

---

Reference

1. Colhoun HM, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicenter randomised placebo-controlled trial. Lancet 2004;364:685-96. 

---

Disclaimer

The matter published on this platform has been developed by independent medical writers from various healthcare backgrounds including members of MedWriters Alumni Network. Although great care has been taken in compiling and checking the information, the authors, Rxnews team and its partners or agents, and sponsors shall not be responsible or in any way liable for any errors, omissions, or inaccuracies in this blog article whether arising from negligence or otherwise, however or for any consequences arising therefrom. The inclusion and exclusion of any product do not mention that the publisher advocates or rejects its use generally or in any particular field or field. For any complaints or feedback please write to content@rxnews.in